Innate and Adaptive Immunity
PRRs and TLRs, antibodies, V(D)J diversity, hybridomas, MHC and antigen presentation, T/B activation, complement, hypersensitivity, tolerance and vaccines.
- 28 min
On this page · 22 sections
- Prerequisites
- The Hook: Two Probes, One Fragment
- Innate vs Adaptive Immunity
- Pattern Recognition Receptors and Toll-like Receptors
- Antigens, Immunogens, Haptens and Epitopes
- Antibody Structure, Classes and Functions
- Generation of Antibody Diversity
- Monoclonal Antibodies: the Hybridoma Principle
- MHC and Antigen Presentation
- T and B Cell Activation
- Complement
- Hypersensitivity (Gell and Coombs)
- Tolerance and Autoimmunity
- Immunodeficiency
- Vaccines as an Immunological Concept
- Memory Tricks
- Don’t Confuse
- Common Mistakes
- Practice
- Quick Revision Table
- Key Takeaways
- What’s Next
Prerequisites
- Hormones, Receptors, GPCRs and Second Messengers — TCR and BCR signalling reuse PLCγ, IP₃/DAG, Ca²⁺, Ras–MAPK, and cytokines signal through JAK–STAT.
- DNA Replication, Repair and Recombination — V(D)J joining is finished by non-homologous end joining (NHEJ).
- Cell Cycle, Cell Division and Cell Death — cytotoxic T cells and NK cells kill by triggering apoptosis; pyroptosis follows inflammasome activation.
- Immunotechniques, Histochemistry and Microscopy — ELISA, flow cytometry and Western blots use the antibodies this page explains.
The Hook: Two Probes, One Fragment
How CSIR NET asks it. Part B: which TLR sees which ligand, which Ig class does what, which enzyme makes which kind of diversity, which MHC presents to which T cell, which complement protein forms the C3 convertase, which hypersensitivity type fits an example. Part C: knockout and deficiency phenotypes, complement assay patterns, hybridoma selection logic, MHC-restriction experiments and gene-segment arithmetic.
Innate vs Adaptive Immunity
| Feature | Innate | Adaptive |
|---|---|---|
| Receptors | Germline-encoded pattern recognition receptors (PRRs), same on every cell of a type | Rearranged TCR and BCR, one specificity per clone |
| Recognises | Conserved microbial patterns (PAMPs) and damage signals (DAMPs) | Specific epitopes on any molecule |
| Speed | Minutes to hours | Days (primary); faster on re-exposure |
| Memory | Essentially none (classically) | Yes: memory B and T cells |
| Cells | Neutrophils, macrophages, dendritic cells, NK cells, mast cells, eosinophils, basophils, innate lymphoid cells | T cells, B cells |
| Soluble factors | Complement, acute-phase proteins, interferons, defensins | Antibodies |
The two systems are not separate. Dendritic cells sense pathogens through PRRs and then activate naive T cells; antibodies direct complement and phagocytes to targets.
Barriers and innate effectors
- Physical and chemical barriers: skin (keratin, low pH, fatty acids), mucus and cilia, stomach acid, lysozyme in tears and saliva (cleaves peptidoglycan), defensins and other antimicrobial peptides, and competition from resident commensal microbes.
- Phagocytes: neutrophils (first to arrive, short-lived) and macrophages (long-lived, also present antigen). Killing in the phagolysosome uses the NADPH oxidase (respiratory burst), lysosomal enzymes and nitric oxide.
- Dendritic cells (DCs): the link to adaptive immunity; they capture antigen in tissues and migrate to lymph nodes to present it.
- NK cells: kill cells that have lost MHC class I (“missing self”) or display stress ligands, using perforin and granzymes; also kill antibody-coated cells by ADCC through FcγRIII (CD16).
- Mast cells, basophils, eosinophils: granule-rich cells for inflammation, allergy and anti-helminth defence.
Pattern Recognition Receptors and Toll-like Receptors
Drosophila Toll was first known as a dorsoventral patterning gene; flies lacking Toll signalling were found to be highly susceptible to fungal infection. Mammalian homologues, the Toll-like receptors, have an extracellular leucine-rich repeat domain and a cytoplasmic TIR domain.
| Receptor | Location | Ligand (PAMP) |
|---|---|---|
| TLR4 (with MD-2; CD14 helps) | Plasma membrane (also signals from endosomes) | LPS of Gram-negative bacteria |
| TLR2 (with TLR1 or TLR6) | Plasma membrane | Lipoproteins and lipopeptides, lipoteichoic acid |
| TLR5 | Plasma membrane | Flagellin |
| TLR3 | Endosome | dsRNA |
| TLR7 / TLR8 | Endosome | ssRNA |
| TLR9 | Endosome | Unmethylated CpG DNA |
| NOD1 / NOD2 (NLRs) | Cytosol | Peptidoglycan fragments (NOD2: muramyl dipeptide) |
| NLRP3 inflammasome | Cytosol | Many danger signals (K⁺ efflux, crystals, extracellular ATP) |
| RIG-I, MDA5 (RLRs) | Cytosol | Viral RNA (RIG-I: 5′-triphosphate RNA) |
| cGAS → STING | Cytosol | Cytosolic dsDNA |
| C-type lectins (Dectin-1, mannose receptor) | Plasma membrane | β-glucans, mannose-rich glycans |
Nucleic-acid-sensing TLRs sit in endosomes, which keeps them away from the host’s own extracellular DNA and RNA.
flowchart LR A["Surface TLRs
TLR1/2/4/5/6"] --> M["MyD88"] B["Endosomal TLR7/8/9"] --> M C["Endosomal TLR3"] --> T["TRIF"] A2["TLR4 (endosome)"] --> T M --> I["IRAK–TRAF6 → IKK"] I --> N["NF-κB → TNF-α, IL-1β, IL-6, IL-12
B7 (CD80/86) up on DCs"] T --> R["IRF3 → type I interferon"] T --> N
- MyD88 is used by every TLR except TLR3; TLR4 is the one that uses both MyD88 and TRIF.
- Inflammasome: NLRP3 recruits the adaptor ASC and pro-caspase-1. Active caspase-1 cleaves pro-IL-1β and pro-IL-18 to their active forms and cleaves gasdermin D, whose pores cause pyroptosis. Two signals are needed: priming (NF-κB makes pro-IL-1β and NLRP3) and activation.
- Type I interferons (IFN-α, IFN-β) act through JAK–STAT to put neighbouring cells into an antiviral state.
Inflammation
The classic signs are rubor, calor, tumor, dolor (redness, heat, swelling, pain), with loss of function. Mediators: histamine (mast cells; vasodilation, permeability), prostaglandins and leukotrienes (arachidonic acid), bradykinin, complement C3a and C5a, and cytokines TNF-α, IL-1, IL-6. IL-6 drives the liver to make acute-phase proteins (CRP, mannose-binding lectin, fibrinogen).
Leukocytes leave blood in steps: selectin-mediated rolling → chemokine signalling activates integrins (LFA-1, a β2 integrin) → firm adhesion to ICAM-1 → diapedesis between endothelial cells → migration up the chemokine gradient. Integrins and selectins are covered on the adhesion and junctions page.
Antigens, Immunogens, Haptens and Epitopes
| Term | Meaning |
|---|---|
| Antigen | Any molecule that binds an antibody or a TCR (as peptide–MHC) |
| Immunogen | A molecule that induces an immune response. Every immunogen is an antigen; not every antigen is an immunogen |
| Hapten | A small molecule that binds antibody but cannot induce a response alone; becomes immunogenic when coupled to a carrier protein (Landsteiner) |
| Epitope (antigenic determinant) | The part of an antigen actually bound |
| Paratope | The antigen-binding site on the antibody |
B-cell epitopes lie on the accessible surface of native antigen and are often conformational (discontinuous residues brought together by folding). T-cell epitopes are linear peptides produced by processing and bound in an MHC groove, so they can come from anywhere in the protein, including its interior.
Immunogenicity rises with foreignness, size, chemical complexity (proteins > polysaccharides > lipids and nucleic acids alone), the ability to be processed and presented, an appropriate dose and route, and adjuvants. Adjuvants supply innate signals (often PRR ligands) that raise B7 on dendritic cells, which is why they help.
Antibody Structure, Classes and Functions
An IgG molecule has two identical heavy (H) chains and two identical light (L) chains joined by disulphide bonds into a Y. Light chains are κ or λ. Each chain is built from immunoglobulin domains (about 110 residues, a β-sandwich held by an intrachain disulphide).
- Light chain: V\(_L\) + C\(_L\).
- Heavy chain: V\(_H\) + C\(_H\)1 + hinge + C\(_H\)2 + C\(_H\)3 (IgG, IgA, IgD). IgM and IgE have no hinge and an extra C\(_H\)4 domain.
- Each V domain has three hypervariable loops (CDR1–3); the six CDRs of V\(_H\) and V\(_L\) form the paratope. CDR3 is the most variable because it spans the gene-segment junctions.
- Papain cuts above the hinge disulphides: 2 Fab + 1 Fc. Pepsin cuts below them: one bivalent F(ab′)₂ plus small Fc fragments.
| Class | Form in serum | Key features and functions |
|---|---|---|
| IgG | Monomer | Most abundant in serum; longest half-life; crosses the placenta (FcRn); opsonisation, ADCC, neutralisation; activates complement (subclass-dependent); main class of the secondary response |
| IgM | Pentamer with J chain (monomer on B-cell surface) | First antibody of a primary response; best complement activator; high avidity (10 sites) |
| IgA | Monomer in serum; dimer with J chain and secretory component in secretions | Mucosal immunity; transcytosed by the polymeric Ig receptor; in milk, tears, saliva |
| IgE | Monomer | Lowest serum level; binds FcεRI on mast cells and basophils; allergy and anti-helminth defence |
| IgD | Monomer | Co-expressed with IgM on naive mature B cells (alternative splicing); little in serum |
Serum concentration order: IgG > IgA > IgM > IgD > IgE. On the B-cell surface the immunoglobulin pairs with Igα/Igβ (CD79a/b), whose ITAMs carry the signal. Membrane and secreted forms of one heavy chain come from alternative RNA processing at the 3′ end (see Transcription and RNA Processing).
Generation of Antibody Diversity
V(D)J recombination
Heavy-chain loci contain multiple V, D and J segments; light-chain loci have V and J only. In each developing B cell one segment of each type is joined.
- RAG1/RAG2 recognise recombination signal sequences (RSS): a conserved heptamer and nonamer separated by a 12 bp or 23 bp spacer.
- 12/23 rule: joining occurs only between a segment flanked by a 12-bp spacer RSS and one flanked by a 23-bp spacer RSS. In the heavy chain, V and J carry 23-bp RSSs and D carries 12-bp RSSs on both sides, so V cannot join J directly; D must come between.
- RAG cuts make hairpin coding ends and blunt signal ends. Artemis (with DNA-PKcs) opens the hairpins, often off-centre, adding palindromic P-nucleotides; TdT adds random, non-templated N-nucleotides; exonucleases trim. Ku70/80, XRCC4 and DNA ligase IV (NHEJ) seal the joint.
- Coding joints are imprecise; signal joints are precise (signal joints in deletional rearrangement form a circle that is lost).
Order in B-cell development: heavy chain D→J then V→DJ (pro-B) → μ chain pairs with the surrogate light chain (λ5 + VpreB) as the pre-BCR (pre-B), which signals proliferation and allelic exclusion → light chain rearranges (κ first, then λ) → immature B with surface IgM.
flowchart LR G["Germline
V…D…J…Cμ"] -->|"RAG: D→J"| DJ["DJ joined"] DJ -->|"RAG: V→DJ"| VDJ["VDJ–Cμ
pre-BCR"] VDJ -->|"light chain V→J"| IgM["Surface IgM
(+ IgD by splicing)"] IgM -->|"antigen + Tfh help
AID in germinal centre"| SHM["Somatic hypermutation
→ affinity maturation"] IgM -->|"AID at switch regions
+ cytokines, CD40L"| CSR["Class switch
IgG, IgA, IgE"]
The five sources of diversity
| Source | Mechanism | When |
|---|---|---|
| Multiple germline segments | Many V, D, J to choose from | Antigen-independent (bone marrow) |
| Combinatorial joining | Any V with any (D) J | Antigen-independent |
| Junctional diversity | Imprecise joining, P- and N-nucleotides (TdT) | Antigen-independent |
| Combinatorial H–L pairing | Any heavy with any light chain | Antigen-independent |
| Somatic hypermutation (SHM) | Point mutations in rearranged V regions by AID | Antigen-dependent, germinal centres |
For a hypothetical species with \(n_V, n_D, n_J\) heavy-chain segments and light-chain sets \(\kappa\) and \(\lambda\):
$$\text{Combinations} = (n_V n_D n_J)_H \times \left[(n_V n_J)_\kappa + (n_V n_J)_\lambda\right]$$Junctional diversity and SHM multiply this further, which is why the real repertoire is far larger than the combinatorial number.
Somatic hypermutation and affinity maturation
In germinal centres, activation-induced cytidine deaminase (AID) deaminates C to U in rearranged V regions. Repair of these lesions introduces point mutations at a rate far above the background. B cells whose mutated BCR binds antigen (displayed on follicular dendritic cells) better win help from T follicular helper (Tfh) cells and survive: affinity maturation. This is why antibody affinity rises over the course of a response and after boosting.
Class switch recombination (CSR)
AID also acts at repetitive switch (S) regions upstream of each C\(_H\) gene (except Cδ). Recombination between Sμ and a downstream S region deletes the intervening constant genes. The VDJ is unchanged, so specificity is kept; only the effector function changes. CSR needs CD40–CD40L contact with a T cell and is directed by cytokines (mouse examples: IL-4 → IgG1 and IgE; IFN-γ → IgG2a; TGF-β → IgA). IgM to IgD is not switching; it is alternative splicing.
Monoclonal Antibodies: the Hybridoma Principle
Köhler and Milstein (1975) solved a mismatch: B cells make a single specificity but die in culture; myeloma cells are immortal but make an irrelevant (or no) antibody. Fusing the two gives a hybridoma, an immortal cell secreting one antibody.
The selection logic:
- Spleen B cells from an immunised mouse are fused with a myeloma line that lacks HGPRT and secretes no antibody of its own (polyethylene glycol is the usual fusogen).
- Cells are grown in HAT medium: aminopterin blocks dihydrofolate reductase and therefore de novo purine and thymidylate synthesis. Cells survive only through the salvage pathway, which needs HGPRT (to use hypoxanthine) and thymidine kinase (to use thymidine).
- Unfused myeloma cells die (no HGPRT). Unfused B cells die (finite lifespan). Hybrids survive: HGPRT from the B cell, immortality from the myeloma.
- Wells are screened (for example by ELISA) for the wanted specificity and cloned by limiting dilution, so each line descends from one cell.
Mouse antibodies are themselves immunogenic in humans, so therapeutic antibodies are made chimeric (mouse V, human C), humanised (only mouse CDRs grafted into a human framework) or fully human.
MHC and Antigen Presentation
T cells see antigen only as peptide bound to an MHC molecule on another cell: MHC restriction (Zinkernagel and Doherty). Human MHC = HLA, on chromosome 6: class I HLA-A, -B, -C; class II HLA-DP, -DQ, -DR; class III genes include complement C2, C4, factor B and TNF. Mouse MHC = H-2 (chromosome 17). MHC genes are highly polymorphic and codominantly expressed.
| Feature | MHC class I | MHC class II |
|---|---|---|
| Chains | α chain (α1, α2, α3) + β₂-microglobulin (not MHC-encoded) | α chain + β chain (each two domains) |
| Groove formed by | α1 + α2 | α1 + β1 |
| Groove ends | Closed | Open |
| Peptide length | 8–10 residues (usually 9) | Longer (about 13–25); ends overhang |
| Expressed on | All nucleated cells | Professional APCs: DCs, macrophages, B cells; thymic epithelium |
| Peptide source | Cytosolic (endogenous) proteins | Endocytosed (exogenous) proteins |
| Presents to | CD8 T cells (CD8 binds α3) | CD4 T cells (CD4 binds β2) |
The two pathways
flowchart TB
subgraph I["Class I: cytosolic pathway"]
P1["Cytosolic protein"] --> PR["Proteasome
(immunoproteasome after IFN-γ)"]
PR --> TAP["TAP1/TAP2 pumps peptide into ER"]
TAP --> PLC["Peptide-loading complex:
tapasin, calreticulin, ERp57; ERAP trims"]
PLC --> S1["Class I–peptide to surface → CD8 T cell"]
end
subgraph II["Class II: endocytic pathway"]
E1["Endocytosed protein"] --> EN["Endosome/lysosome proteases"]
ER2["Class II + invariant chain (Ii) in ER"] --> MIIC["Ii degraded → CLIP left in groove"]
EN --> DM["HLA-DM swaps CLIP for peptide"]
MIIC --> DM
DM --> S2["Class II–peptide to surface → CD4 T cell"]
end- Invariant chain (Ii, CD74) blocks the class II groove in the ER and targets class II to endosomes. CLIP is the Ii fragment left in the groove; HLA-DM (a non-classical class II molecule) catalyses its exchange for peptide.
- Without TAP or β₂-microglobulin, class I is unstable and little reaches the surface; such mice and patients have very few CD8 T cells.
Cross-presentation
Some dendritic cells (the cDC1 subset; CD8α⁺ DCs in mouse spleen) load exogenous antigen onto class I. This lets naive CD8 T cells be primed against antigens made only in other cells (for example tumour cells, or cells infected by viruses that do not infect DCs). Routes include escape of phagocytosed protein into the cytosol for proteasomal processing and TAP transport, and loading within the phagosome.
T and B Cell Activation
T cells: three signals
| Signal | Molecules | Outcome |
|---|---|---|
| 1. Antigen | TCR + CD4/CD8 binds peptide–MHC; Lck phosphorylates CD3/ζ ITAMs; ZAP-70 → LAT, SLP-76 → PLCγ1 | IP₃ → Ca²⁺ → calcineurin → NFAT; DAG → PKCθ → NF-κB; Ras → MAPK → AP-1 |
| 2. Co-stimulation | CD28 on T cell binds B7-1 (CD80) / B7-2 (CD86) on an activated APC | IL-2 and CD25 (IL-2Rα) induced; survival, proliferation |
| 3. Cytokines | Polarising cytokines from the APC and environment | Choice of effector fate |
Signal 1 without signal 2 → anergy. Since B7 is induced on DCs by PRR signalling, the innate system decides when adaptive responses start. CTLA-4 binds B7 with higher affinity than CD28 and inhibits; PD-1 (ligands PD-L1/PD-L2) also inhibits. Blocking these “checkpoints” with antibodies releases anti-tumour T cells. Cyclosporin A and tacrolimus inhibit calcineurin; rapamycin inhibits mTOR downstream of the IL-2 receptor.
| CD4 subset | Induced by | Master regulator | Signature output | Main job |
|---|---|---|---|---|
| Th1 | IL-12, IFN-γ | T-bet | IFN-γ | Macrophage activation, intracellular microbes |
| Th2 | IL-4 | GATA3 | IL-4, IL-5, IL-13 | Helminths, IgE, allergy |
| Th17 | TGF-β + IL-6 (IL-23 sustains) | RORγt | IL-17, IL-22 | Extracellular bacteria and fungi; neutrophils |
| Tfh | IL-6, IL-21 | Bcl-6 | IL-21, CD40L | B-cell help in germinal centres |
| Treg (induced) | TGF-β + IL-2 | FoxP3 | IL-10, TGF-β | Suppression, tolerance |
CD8 cytotoxic T cells kill targets by perforin and granzymes and by Fas ligand, both of which trigger apoptosis.
B cells: T-dependent vs T-independent
The BCR signals through Igα/Igβ (Syk, Btk, PLCγ2). The co-receptor CD21 (CR2)–CD19–CD81 binds complement fragment C3d on the antigen and lowers the activation threshold, another link from innate to adaptive.
| T-dependent (TD) | T-independent (TI) | |
|---|---|---|
| Antigen | Proteins | TI-1: polyclonal activators such as LPS (at high dose). TI-2: repetitive polysaccharides that crosslink many BCRs |
| Help | B cell presents antigen peptide on class II to a Tfh cell primed by the same antigen; CD40L–CD40 + cytokines | None (TI-2 may get some help from cytokines) |
| Germinal centre | Yes | Little or none |
| Class switching and SHM | Yes | Limited; mostly IgM |
| Memory | Strong | Weak |
| Infants | Respond well | Poor responses to TI-2 antigens |
Linked recognition (hapten–carrier effect): a B cell specific for a hapten gets help from T cells specific for the carrier, because it internalises the conjugate and presents carrier peptides. This is exactly how conjugate vaccines turn a polysaccharide into a T-dependent antigen.
Primary vs secondary response: the primary response has a lag, peaks lower and is dominated by IgM; the secondary response is faster, larger, longer-lasting, mainly IgG (or IgA/IgE) and of higher affinity.
Complement
flowchart TB CL["Classical:
C1q binds antigen-bound IgM/IgG
C1r, C1s"] --> C42["C4b2a
(classical/lectin C3 convertase)"] LE["Lectin:
MBL or ficolins bind microbial sugars
MASP-1, MASP-2"] --> C42 AL["Alternative:
spontaneous C3 'tick-over'
factor B, factor D, properdin"] --> C3B["C3bBb
(alternative C3 convertase)"] C42 --> C3["C3 → C3a + C3b"] C3B --> C3 C3 --> C5["C5 convertases
C4b2a3b / C3bBb3b"] C3 --> OP["C3b, iC3b: opsonisation
C3d: B-cell co-receptor"] C5 --> C5A["C5a: chemotaxis, anaphylatoxin"] C5 --> MAC["C5b + C6 + C7 + C8 + many C9
= Membrane attack complex"]
- C3 is the hub of all three pathways. Its internal thioester lets C3b attach covalently to nearby surfaces.
- Older and most exam texts call the large C2 fragment C2a, giving C4b2a; some newer texts rename it C2b. Learn the structure, not the letter.
- Functions: lysis (MAC), opsonisation (C3b, iC3b), inflammation (C3a, C5a anaphylatoxins; C5a is strongly chemotactic), and clearance of immune complexes.
- Regulators protect host cells: C1 inhibitor (deficiency: hereditary angioedema), DAF (CD55) and MCP (CD46) accelerate convertase decay or act as cofactors; factor H and factor I inactivate C3b; CD59 blocks MAC assembly. Loss of GPI-anchored DAF and CD59 from red cells causes paroxysmal nocturnal haemoglobinuria.
| Deficiency | Typical consequence |
|---|---|
| Early classical (C1q, C2, C4) | Immune-complex disease, SLE-like |
| C3 | Severe recurrent pyogenic infections |
| Terminal (C5–C9) | Recurrent Neisseria infections |
| C1 inhibitor | Hereditary angioedema |
Hypersensitivity (Gell and Coombs)
| Type | Mediator | Mechanism | Timing | Classic examples |
|---|---|---|---|---|
| I Immediate | IgE | Allergen crosslinks IgE on mast cells → histamine, leukotrienes, prostaglandins | Minutes | Anaphylaxis, hay fever, allergic asthma, urticaria |
| II Cytotoxic | IgG/IgM against cell-surface or matrix antigens | Complement lysis, opsonisation, ADCC; or receptor stimulation/blockade | Hours | Transfusion reactions, haemolytic disease of the newborn, autoimmune haemolytic anaemia, Goodpasture syndrome; Graves’ disease and myasthenia gravis (receptor antibodies) |
| III Immune complex | Soluble antigen–antibody complexes | Deposition in vessels, kidney, joints → complement, neutrophils | Hours | Serum sickness, Arthus reaction, SLE |
| IV Delayed-type | T cells (Th1, CD8) | Cytokines activate macrophages; direct killing | 24–72 h | Tuberculin skin test, contact dermatitis (nickel), granulomas |
Types I–III are antibody-mediated and can be transferred with serum; type IV is cell-mediated and transferred with T cells. Rh incompatibility in pregnancy (type II) is covered in Blood and Cardiovascular System.
Tolerance and Autoimmunity
Central tolerance
- T cells (thymus): double-negative → double-positive (CD4⁺CD8⁺) thymocytes. Positive selection in the cortex keeps cells whose TCR binds self-MHC weakly (MHC restriction; CD4 vs CD8 lineage choice). Negative selection in the medulla deletes cells that bind self-peptide–MHC strongly. AIRE lets medullary epithelial cells express tissue-restricted self-antigens (insulin, for example).
- B cells (bone marrow): strongly self-reactive immature B cells undergo receptor editing (new light-chain rearrangement), clonal deletion or anergy.
Peripheral tolerance: anergy (signal 1 without 2), regulatory T cells (CD4⁺CD25⁺FoxP3⁺), activation-induced cell death via Fas, and antigens hidden from lymphocytes (immunologically privileged sites).
When tolerance fails
- Genes: AIRE loss → multi-organ autoimmunity (APECED); FOXP3 loss → IPEX (scurfy in mice); Fas/FasL defects → lymphoproliferation; HLA associations (HLA-B27 with ankylosing spondylitis; HLA-DR3/DR4 with type 1 diabetes).
- Triggers: molecular mimicry (antibodies against a streptococcal M protein cross-react with heart tissue in rheumatic fever), release of sequestered antigens after injury, bystander activation during inflammation.
| Organ-specific | Systemic |
|---|---|
| Type 1 diabetes, Hashimoto thyroiditis, Graves’ disease, myasthenia gravis, multiple sclerosis | SLE, rheumatoid arthritis |
Immunodeficiency
Primary immunodeficiencies are inherited; secondary ones are acquired. Read each primary defect from the pathway it breaks:
| Defect | Missing step | Result |
|---|---|---|
| RAG1/RAG2 deficiency | V(D)J recombination | No T or B cells (NK present): SCID |
| X-linked SCID (common γ chain, IL2RG) | Signalling by IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 receptors | No T or NK cells; B cells present but without T help |
| ADA deficiency | Purine salvage; toxic deoxyadenosine metabolites | Lymphocyte death: SCID |
| X-linked agammaglobulinaemia (BTK) | Pre-BCR signalling | B-cell arrest at pre-B; all Ig classes very low |
| X-linked hyper-IgM (CD40L) | T-cell help for CSR | High/normal IgM, little IgG, IgA, IgE |
| AID deficiency | SHM and CSR | Hyper-IgM (autosomal) |
| DiGeorge (22q11.2 deletion) | Thymus (and parathyroid) development | Few T cells; hypocalcaemia |
| MHC class II deficiency (“bare lymphocyte”) | Class II expression | Few CD4 T cells |
| TAP deficiency | Class I loading | Few CD8 T cells |
| Chronic granulomatous disease | Phagocyte NADPH oxidase | Phagocytes ingest but cannot kill; granulomas |
| Leukocyte adhesion deficiency type 1 (CD18, β2 integrin) | Firm adhesion and extravasation | Neutrophilia in blood, few in tissues |
Secondary causes: malnutrition, immunosuppressive and cytotoxic drugs, ageing, loss of the spleen, and infections that deplete immune cells (HIV depletes CD4 T cells). For disease details stay with Kuby and the host–pathogen topic of this chapter.
Vaccines as an Immunological Concept
Active immunisation stimulates the recipient’s own lymphocytes and gives memory. Passive immunisation transfers ready-made antibody (maternal IgG across the placenta, IgA in milk, antibody preparations): immediate but temporary, with no memory.
| Vaccine type | What the immune system meets | Response and memory |
|---|---|---|
| Live attenuated | A weakened replicating organism; antigen made inside host cells | Antibody and CD8 T cells via class I; long-lived memory, often few doses. Not for the immunocompromised |
| Inactivated (killed) | Non-replicating whole organism | Mainly antibody and CD4 help; boosters and adjuvant usually needed |
| Subunit / recombinant protein | Purified protein antigens | Antibody and CD4 help; needs adjuvant; little CD8 |
| Toxoid | Inactivated toxin | Neutralising antibody against the toxin |
| Polysaccharide | Capsular sugar alone | T-independent: IgM, little switching, weak memory, poor in infants |
| Conjugate | Polysaccharide coupled to a carrier protein | T-dependent via linked recognition: IgG, affinity maturation, memory, works in infants |
| Nucleic acid (mRNA, DNA) and viral vector | Antigen made inside host cells from delivered genetic instructions | Antibody and CD8 T cells (class I presentation), plus CD4 help |
The common thread: where the antigen is made decides the MHC pathway. Antigen synthesised inside host cells reaches class I and primes CD8 T cells; antigen given as protein is mainly exogenous and favours class II, CD4 help and antibody (except through cross-presentation).
Memory Tricks
Don’t Confuse
| This | vs | That |
|---|---|---|
| Antigen: binds antibody/TCR | vs | Immunogen: induces a response |
| B-cell epitope: surface, often conformational | vs | T-cell epitope: linear peptide on MHC |
| Papain: 2 Fab + Fc | vs | Pepsin: F(ab′)₂ |
| Junctional diversity: TdT, P/N-nucleotides; before antigen | vs | Somatic hypermutation: AID; after antigen, in germinal centres |
| Class switching: DNA deletion, new C region, same VDJ | vs | IgM + IgD co-expression: alternative splicing, no DNA change |
| Class I: closed groove, 8–10-mers, all nucleated cells, CD8 | vs | Class II: open groove, longer peptides, APCs, CD4 |
| TAP: carries peptides into the ER (class I) | vs | Invariant chain / HLA-DM: protect and load class II |
| Anergy: signal 1 without CD28–B7 | vs | Deletion: strong self-recognition in thymus |
| CTLA-4: inhibitory, high B7 affinity | vs | CD28: activating B7 receptor |
| Classical/lectin C3 convertase: C4b2a | vs | Alternative C3 convertase: C3bBb (stabilised by properdin) |
| Type II: antibody against cell-bound antigen | vs | Type III: soluble immune complexes deposited |
| Polysaccharide vaccine: TI, IgM, weak memory | vs | Conjugate vaccine: TD, IgG, memory |
Common Mistakes
Practice
All questions below are original practice questions written in CSIR NET style. They are not previous-year questions.
Level 1: Foundation
- Which TLR recognises bacterial flagellin?
- Which enzyme adds non-templated N-nucleotides at V(D)J junctions?
- Which molecule exchanges CLIP for antigenic peptide in the MHC class II pathway?
Answers
- TLR5.
- Terminal deoxynucleotidyl transferase (TdT).
- HLA-DM (H-2M in mouse).
Level 2: Part B Style
Q1 (practice). A myeloma cell line used for hybridoma production lacks HGPRT. In HAT medium after fusion with spleen cells, which cells grow out?
- (a) Unfused myeloma cells only
- (b) Unfused spleen B cells only
- (c) Myeloma–spleen cell hybrids only
- (d) Myeloma–myeloma fusions and hybrids
Answer and explanation
(c). Aminopterin blocks de novo nucleotide synthesis. Myeloma cells (and myeloma–myeloma fusions) lack HGPRT and cannot use the salvage pathway, so they die. Unfused B cells have HGPRT but a finite lifespan. Only hybrids combine HGPRT (from the B cell) with immortality (from the myeloma).
Q2 (practice). Mice lacking β₂-microglobulin would be expected to show:
- (a) Absence of B cells
- (b) Very few mature CD8 T cells
- (c) Very few mature CD4 T cells
- (d) No complement activity
Answer and explanation
(b). Without β₂m, class I molecules are unstable and barely reach the cell surface, so thymocytes cannot be positively selected into the CD8 lineage. CD4 T cells (class II) and B cells develop.
Q3 (practice). A boy has recurrent infections, normal-to-high serum IgM, and very low IgG, IgA and IgE. His B cells switch class normally when stimulated in culture with anti-CD40 antibody and IL-4. The most likely defect is in:
- (a) AID
- (b) CD40 ligand on T cells
- (c) BTK
- (d) RAG1
Answer and explanation
(b). Hyper-IgM with B cells that can switch when CD40 is engaged artificially means the B cells are intrinsically normal; the missing signal is T-cell CD40L (X-linked, fitting a boy). An AID defect would block switching even in culture. BTK and RAG defects remove B cells.
Q4 (practice). A newborn has a maternal anti-toxin IgG titre of 1:1,280. Protection is assumed to require a titre of at least 1:80, and IgG is assumed to decay with a half-life of 21 days with no new synthesis. For roughly how long is the infant protected?
- (a) 42 days
- (b) 63 days
- (c) 84 days
- (d) 105 days
Answer and explanation
(c). 1,280 → 640 → 320 → 160 → 80 is 4 half-lives: \(t = 21 \times \log_2(1280/80) = 21 \times 4 = 84\) days. This is passive immunity: no memory is formed, which is why active immunisation is still needed.
Level 3: Part C Style
Q1 (practice). A hypothetical mammal has, in its germline, 40 functional V\(_H\), 25 D and 6 J\(_H\) segments; 35 V\(_\kappa\) and 5 J\(_\kappa\); 30 V\(_\lambda\) and 4 J\(_\lambda\).
(i) How many different heavy chains and light chains can combinatorial joining alone produce? (ii) How many antibody specificities can result from combinatorial joining and H–L pairing? (iii) Which statement is correct?
- (a) The real repertoire is smaller than (ii) because of allelic exclusion.
- (b) The real repertoire is much larger than (ii) because of junctional diversity and somatic hypermutation.
- (c) Somatic hypermutation adds diversity before antigen exposure.
- (d) Class switching increases the number of specificities.
Answer and worked solution
- Heavy chains: \(40 \times 25 \times 6 = \) 6,000. Light chains: κ \(35 \times 5 = 175\); λ \(30 \times 4 = 120\); total 295.
- Pairing: \(6000 \times 295 = \) 1,770,000 (about \(1.8 \times 10^6\)).
- (b). Imprecise joining, P- and N-nucleotides (mostly in CDR3) and antigen-driven SHM multiply the combinatorial number many-fold. Allelic exclusion makes each B cell express one specificity; it does not shrink the population repertoire (a). SHM is antigen-dependent (c). Class switching changes the constant region, not specificity (d).
Q2 (practice). Complement function is tested in four patients’ sera. CH50 measures lysis by the classical pathway (and terminal components); AH50 measures lysis by the alternative pathway (and terminal components). Results as percent of normal:
| Patient | CH50 | AH50 | Clinical note |
|---|---|---|---|
| P | < 5 | 95 | Rash, arthritis, anti-nuclear antibodies |
| Q | < 5 | < 5 | Recurrent Neisseria infections |
| R | 100 | < 5 | Recurrent infections |
| S | < 5 | < 5 | Severe recurrent pyogenic infections from infancy |
Which assignment is most consistent?
- (a) P: C2; Q: C7; R: factor B; S: C3
- (b) P: C3; Q: C2; R: C7; S: factor D
- (c) P: factor B; Q: C4; R: C2; S: C9
- (d) P: C7; Q: C3; R: C1q; S: factor B
Answer and explanation
(a).
- P: only the classical pathway is lost, so the defect is in C1, C4 or C2. SLE-like disease fits an early classical deficiency (poor immune-complex clearance). C2 fits.
- Q: both assays fail, so the defect is in a shared component (C3 or C5–C9). Recurrent Neisseria points to a terminal component such as C7.
- R: only the alternative pathway is lost: factor B, factor D or properdin.
- S: both fail with severe pyogenic infections from infancy: C3, the hub of opsonisation.
Q3 (practice). CD8 T cells are taken from mouse strain A (H-2ᵏ) immunised with cells expressing protein X in their cytosol. They are tested for killing of target cells in a chromium-release assay:
| Target cells | MHC | Express protein X? | Specific lysis |
|---|---|---|---|
| T1 | H-2ᵏ | Yes | 62% |
| T2 | H-2ᵏ | No | 3% |
| T3 | H-2ᵇ | Yes | 4% |
| T4 | H-2ᵏ, TAP-deficient | Yes | 6% |
| T5 | H-2ᵏ, TAP-deficient, pulsed with a synthetic X peptide | No (peptide only) | 58% |
Which statements are correct?
- A. Recognition requires both protein X and self MHC (H-2ᵏ).
- B. Protein X must be processed and transported into the ER to be seen on intact cells.
- C. TAP is required for the CTL to bind peptide–MHC on the target surface.
- D. The epitope is presented on MHC class II.
Options: (a) A and B only (b) A, B and C (c) B and D only (d) A and D only
Answer and explanation
(a).
- A is correct: T1 vs T2 shows antigen specificity; T1 vs T3 shows MHC restriction (same antigen on a different MHC is not recognised).
- B is correct: T4 makes protein X but, without TAP, cytosolic peptides do not reach class I.
- C is wrong: T5 shows that once peptide is loaded from outside onto surface class I, TAP-deficient cells are killed. TAP is needed for loading, not for recognition.
- D is wrong: CD8 T cells, cytosolic antigen and TAP dependence all mark class I.
Quick Revision Table
| Item | Fact |
|---|---|
| PRRs | TLRs, NLRs (NOD1/2, NLRP3), RLRs (RIG-I, MDA5), cGAS–STING, C-type lectins |
| TLR ligands | 4 LPS; 2 (+1/6) lipopeptides; 5 flagellin; 3 dsRNA; 7/8 ssRNA; 9 CpG DNA |
| TLR adaptors | MyD88 all but TLR3; TRIF for TLR3 and TLR4 |
| Inflammasome | NLRP3 + ASC + caspase-1 → IL-1β, IL-18, gasdermin D (pyroptosis) |
| Extravasation | Selectin rolling → chemokine → integrin (LFA-1–ICAM-1) → diapedesis |
| Hapten | Antigenic, not immunogenic without carrier |
| Ig structure | 2H + 2L; κ or λ; CDR1–3, CDR3 most variable; papain 2 Fab + Fc; pepsin F(ab′)₂ |
| Ig classes | IgG placenta; IgM pentamer, first, complement; IgA dimer in secretions; IgE mast cells; IgD naive B |
| V(D)J | RAG1/2, RSS 12/23 rule; Artemis (P), TdT (N), NHEJ ligase IV |
| AID | SHM (affinity maturation) and CSR (switch regions) |
| Hybridoma | HGPRT⁻ myeloma + B cell; HAT selects hybrids; limiting-dilution cloning |
| MHC I | α + β₂m; 8–10-mers; all nucleated cells; CD8; proteasome → TAP → tapasin |
| MHC II | α + β; longer peptides; APCs; CD4; Ii → CLIP → HLA-DM |
| Cross-presentation | cDC1: exogenous antigen on class I → CD8 priming |
| T-cell signals | 1 TCR–pMHC; 2 CD28–B7; 3 cytokines; 1 without 2 = anergy |
| Th subsets | Th1 T-bet IFN-γ; Th2 GATA3 IL-4; Th17 RORγt IL-17; Tfh Bcl-6 IL-21; Treg FoxP3 |
| TD vs TI | TD: CD40L, GC, switch, memory. TI: IgM, weak memory, poor in infants |
| Complement | Classical C1q; lectin MBL/MASP; alternative C3 tick-over, B, D, properdin; MAC C5b–9 |
| Regulators | C1-INH, DAF/CD55, MCP/CD46, factor H, factor I, CD59 |
| Hypersensitivity | I IgE; II antibody on cells; III immune complexes; IV T cells, 24–72 h |
| Tolerance | Thymic +/− selection, AIRE; receptor editing; Tregs (FoxP3); anergy; Fas |
| Primary ID | RAG/IL2RG/ADA SCID; BTK XLA; CD40L hyper-IgM; DiGeorge; CGD; LAD-1 |
| Vaccines | Live and nucleic-acid: CD8 + antibody; killed/subunit/toxoid: antibody; conjugate: TD memory |
Key Takeaways
What’s Next
- Adhesion, Junctions, ECM, Neurotransmission and Haematopoiesis — where lymphocytes and myeloid cells come from, and the selectins and integrins that guide them into tissues.
- Hormones, Receptors, GPCRs and Second Messengers — the kinase cascades and second messengers behind TCR, BCR and cytokine signalling.
- Immunotechniques, Histochemistry and Microscopy — putting monoclonal antibodies to work in ELISA, flow cytometry and immunostaining.
- Back to the chapter overview or Quick Revision.